Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 16:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

60 Degrees to seek FDA MUMS designation for tafenoquine in canine babesiosis, supported by 3 studies showing efficacy and safety in treating babesiosis.